Record Display for the EPA National Library Catalog
RECORD NUMBER: 1 OF 14Main Title | Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CORP Author | Environmental Protection Agency, Washington, DC. National Center for Environmental Assessment. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Publisher | National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Year Published | 2006 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Report Number | EPA/600/R-05/043F | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Number | PB2007-106632 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OCLC Number | 99471710 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Subjects | Risk assessment ; PBPK models ; Target organs ; Internal dose ; Dosimetry modeling ; Physiologically based pharmacokinetic (PBPK) models | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Internet Access | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Holdings |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collation | 1 v. (various pagings) : ill. ; 28 cm. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abstract | The objective of this document is to provide a description of approaches for using physiologically based pharmacokinetic (PBPK) data and models in human health risk assessment. Its primary focus is on the evaluation and use of PBPK models for predicting internal dose at target organs in risk assessment applications. Many of the past efforts on PBPK modeling have focused on water-insoluble gases that cause systemic toxicity (i.e., producing effects remote from the site of exposure) and on some nonvolatile organics. This document primarily draws on the experience and literature resulting from these efforts. These approaches can also be applied to agents such as reactive gases and particulate matter where the target organ is the respiratory tract, generally in conjunction with specialized respiratory tract modeling (e.g., computational fluid dynamic modeling). Guidance concerning alternative approaches to dosimetry modeling should also be consulted for determining a reference concentration (RfC) value (U.S. EPA, 1994). The discussions herein are conceptually applicable, in a broad sense, to many kinds of dosimetry models and a wide range of substances. In developing this document, it was assumed that risk assessors are familiar with some basic concepts of pharmacokinetics and that model developers are familiar with some of the basic concepts of risk assessment; therefore, the document serves as an overview of PBPK modeling and its application in risk assessment. Appropriate references to secondary review articles and reports from which additional information can be obtained are provided. Finally, it is important to realize that the application of PBPK models in risk assessment is evolving. Thus, this document does not specify (or recommend) when the effort to construct and apply PBPK modeling is justified; rather, it highlights some of the benefits of PBPK modeling in risk assessment. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes | August 2006. Includes bibliographical references (p. R1-R17) |